Limiting the Daily Total Nucleated Cell Dose ofCryopreserved Peripheral Blood Stem Cell Productsfor Autologous Transplantation Improves Infusion-Related Safety with No Adverse Impact onHematopoietic Engraftment

Nandita D Khera, Jack Jinneman, Barry E. Storer, Shelly Heimfeld, Megan M. O'Meara, Thomas R. Chauncey, Stephanie J. Lee, Michael Linenberger

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Cryopreserved peripheral blood stem cell (PBSC) products can induce a number of infusion-related adverse reactions, including life-threatening cardiac, neurologic, and other end-organ complications. Preliminary analyses suggested limiting the daily total nucleated cell dose infused might decrease the incidence of these adverse effects. A policy change implemented in December 2007, limiting the total nucleated cell (TNC) dose to <1.63 × 109 TNC/kg/day, allowed us to assess the impact of this intervention on infusion-related safety, infusion schedules, engraftment, and costs in cohorts of patients undergoing autologous stem cell transplants (ASCTs) 2 years before (325 ASCTs in 288 patients) and 2 years after the policy change (519ASCTs in 479 patients). The percentage of autologous transplant patients requiring multiple day infusions increased from 6% to 24%. Concurrently, the incidence of infusion-related grade 3-5 severe infusion-related adverse events (SAEs) decreased significantly, from 4% (13 of 325) prepolicy change to 0.6% (3 of 519) postpolicy change (P < .0004). Multiday infusions were not associated with increased time to neutrophil or platelet engraftment or the costs of transplantation. We conclude that limiting the daily TNC dose improved the safety of this procedure without compromising engraftment or increasing the costs of the procedure.

Original languageEnglish (US)
Pages (from-to)220-228
Number of pages9
JournalBiology of Blood and Marrow Transplantation
Volume18
Issue number2
DOIs
StatePublished - Feb 2012
Externally publishedYes

Fingerprint

Autologous Transplantation
Safety
Costs and Cost Analysis
Stem Cells
Transplants
Incidence
Autografts
Nervous System
Appointments and Schedules
Neutrophils
Blood Platelets
Transplantation
Peripheral Blood Stem Cells

Keywords

  • Autologous stem cell infusions
  • Cryopreserved peripheral blood stem cells
  • Infusion-related adverse events
  • Total nucleated cell dose

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Limiting the Daily Total Nucleated Cell Dose ofCryopreserved Peripheral Blood Stem Cell Productsfor Autologous Transplantation Improves Infusion-Related Safety with No Adverse Impact onHematopoietic Engraftment. / Khera, Nandita D; Jinneman, Jack; Storer, Barry E.; Heimfeld, Shelly; O'Meara, Megan M.; Chauncey, Thomas R.; Lee, Stephanie J.; Linenberger, Michael.

In: Biology of Blood and Marrow Transplantation, Vol. 18, No. 2, 02.2012, p. 220-228.

Research output: Contribution to journalArticle

Khera, Nandita D ; Jinneman, Jack ; Storer, Barry E. ; Heimfeld, Shelly ; O'Meara, Megan M. ; Chauncey, Thomas R. ; Lee, Stephanie J. ; Linenberger, Michael. / Limiting the Daily Total Nucleated Cell Dose ofCryopreserved Peripheral Blood Stem Cell Productsfor Autologous Transplantation Improves Infusion-Related Safety with No Adverse Impact onHematopoietic Engraftment. In: Biology of Blood and Marrow Transplantation. 2012 ; Vol. 18, No. 2. pp. 220-228.
@article{ad3b990f02d2495fac811a2dfa00acb9,
title = "Limiting the Daily Total Nucleated Cell Dose ofCryopreserved Peripheral Blood Stem Cell Productsfor Autologous Transplantation Improves Infusion-Related Safety with No Adverse Impact onHematopoietic Engraftment",
abstract = "Cryopreserved peripheral blood stem cell (PBSC) products can induce a number of infusion-related adverse reactions, including life-threatening cardiac, neurologic, and other end-organ complications. Preliminary analyses suggested limiting the daily total nucleated cell dose infused might decrease the incidence of these adverse effects. A policy change implemented in December 2007, limiting the total nucleated cell (TNC) dose to <1.63 × 109 TNC/kg/day, allowed us to assess the impact of this intervention on infusion-related safety, infusion schedules, engraftment, and costs in cohorts of patients undergoing autologous stem cell transplants (ASCTs) 2 years before (325 ASCTs in 288 patients) and 2 years after the policy change (519ASCTs in 479 patients). The percentage of autologous transplant patients requiring multiple day infusions increased from 6{\%} to 24{\%}. Concurrently, the incidence of infusion-related grade 3-5 severe infusion-related adverse events (SAEs) decreased significantly, from 4{\%} (13 of 325) prepolicy change to 0.6{\%} (3 of 519) postpolicy change (P < .0004). Multiday infusions were not associated with increased time to neutrophil or platelet engraftment or the costs of transplantation. We conclude that limiting the daily TNC dose improved the safety of this procedure without compromising engraftment or increasing the costs of the procedure.",
keywords = "Autologous stem cell infusions, Cryopreserved peripheral blood stem cells, Infusion-related adverse events, Total nucleated cell dose",
author = "Khera, {Nandita D} and Jack Jinneman and Storer, {Barry E.} and Shelly Heimfeld and O'Meara, {Megan M.} and Chauncey, {Thomas R.} and Lee, {Stephanie J.} and Michael Linenberger",
year = "2012",
month = "2",
doi = "10.1016/j.bbmt.2011.06.003",
language = "English (US)",
volume = "18",
pages = "220--228",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Limiting the Daily Total Nucleated Cell Dose ofCryopreserved Peripheral Blood Stem Cell Productsfor Autologous Transplantation Improves Infusion-Related Safety with No Adverse Impact onHematopoietic Engraftment

AU - Khera, Nandita D

AU - Jinneman, Jack

AU - Storer, Barry E.

AU - Heimfeld, Shelly

AU - O'Meara, Megan M.

AU - Chauncey, Thomas R.

AU - Lee, Stephanie J.

AU - Linenberger, Michael

PY - 2012/2

Y1 - 2012/2

N2 - Cryopreserved peripheral blood stem cell (PBSC) products can induce a number of infusion-related adverse reactions, including life-threatening cardiac, neurologic, and other end-organ complications. Preliminary analyses suggested limiting the daily total nucleated cell dose infused might decrease the incidence of these adverse effects. A policy change implemented in December 2007, limiting the total nucleated cell (TNC) dose to <1.63 × 109 TNC/kg/day, allowed us to assess the impact of this intervention on infusion-related safety, infusion schedules, engraftment, and costs in cohorts of patients undergoing autologous stem cell transplants (ASCTs) 2 years before (325 ASCTs in 288 patients) and 2 years after the policy change (519ASCTs in 479 patients). The percentage of autologous transplant patients requiring multiple day infusions increased from 6% to 24%. Concurrently, the incidence of infusion-related grade 3-5 severe infusion-related adverse events (SAEs) decreased significantly, from 4% (13 of 325) prepolicy change to 0.6% (3 of 519) postpolicy change (P < .0004). Multiday infusions were not associated with increased time to neutrophil or platelet engraftment or the costs of transplantation. We conclude that limiting the daily TNC dose improved the safety of this procedure without compromising engraftment or increasing the costs of the procedure.

AB - Cryopreserved peripheral blood stem cell (PBSC) products can induce a number of infusion-related adverse reactions, including life-threatening cardiac, neurologic, and other end-organ complications. Preliminary analyses suggested limiting the daily total nucleated cell dose infused might decrease the incidence of these adverse effects. A policy change implemented in December 2007, limiting the total nucleated cell (TNC) dose to <1.63 × 109 TNC/kg/day, allowed us to assess the impact of this intervention on infusion-related safety, infusion schedules, engraftment, and costs in cohorts of patients undergoing autologous stem cell transplants (ASCTs) 2 years before (325 ASCTs in 288 patients) and 2 years after the policy change (519ASCTs in 479 patients). The percentage of autologous transplant patients requiring multiple day infusions increased from 6% to 24%. Concurrently, the incidence of infusion-related grade 3-5 severe infusion-related adverse events (SAEs) decreased significantly, from 4% (13 of 325) prepolicy change to 0.6% (3 of 519) postpolicy change (P < .0004). Multiday infusions were not associated with increased time to neutrophil or platelet engraftment or the costs of transplantation. We conclude that limiting the daily TNC dose improved the safety of this procedure without compromising engraftment or increasing the costs of the procedure.

KW - Autologous stem cell infusions

KW - Cryopreserved peripheral blood stem cells

KW - Infusion-related adverse events

KW - Total nucleated cell dose

UR - http://www.scopus.com/inward/record.url?scp=84855583658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855583658&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2011.06.003

DO - 10.1016/j.bbmt.2011.06.003

M3 - Article

C2 - 21703976

AN - SCOPUS:84855583658

VL - 18

SP - 220

EP - 228

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 2

ER -